To analyze the effects of Qili Qiangxin Capsule (芪苈强心胶囊) combined with Shakubatrivalsartan Sodium Tablets on the levels of N-terminal pro-brain natriuretic peptide (NT-proBNP), fibrinogen (FIB), D-dimer (D-D) and vascular endothelial growth factor (VEGF) in the patients with chronic heart failure complicated with coronary heart disease, as well as the TCM syndromes and prognosis.

A total of 236 patients with chronic heart failure complicated with coronary heart disease admitted to the Fifth Affiliated Hospital of Xinjiang Medical University from January 2022 to March 2024 were divided into the combined group (118 cases) and the control group (118 cases) by simple random sampling. Both groups were treated with routine comprehensive treatment and Shakubatroxobin Sodium Tablets, while the combined group was treated with Qili Qiangxin Capsule. The course of treatment in both groups was 12 weeks. The changes of NT-proBNP, FIB, D-D and VEGF were detected before and after treatment, and the changes of cardiac function, 6-minute walking distance (6MWD) and TCM syndrome integral were evaluated, and the clinical prognosis of the two groups was evaluated after treatment.

After 12 weeks of treatment, the levels of NT-proBNP, FIB and D-D in both groups decreased, and VEGF increased. After 12 weeks of treatment, the levels of NT-proBNP, FIB and D-D in the combined group were lower than those in the control group, and the VEGF was higher than that in the control group (P<0.05). After 12 weeks of treatment, the levels of LVEF and CO in both groups increased, while the levels of LVEDD and LVESD decreased. After 12 weeks of treatment, the levels of LVEF and CO in the combined group were higher than those in the control group, and the levels of LVEDD and LVESD were lower than those in the control group (P<0.05). After 12 weeks of treatment, the results of 6MWD of both groups was higher than those before treatment, and the TCM syndrome integral was lower than that before treatment. After 12 weeks of treatment, the result of 6MWD of the combined group was higher than that of the control group, and its TCM syndrome score was lower than that of the control group (P<0.05). After 12 weeks of treatment, the total effective rate of the combined group was 87.29% (103/118), which was higher than that of the control group (66.95%, 79/118) (P<0.05).

Combined with Qili Qiangxin Capsule on the basis of Shakubatrivalsartan Sodium Tablets can effectively improve the levels of NT-proBNP, FIB, D-D and VEGF in the patients with chronic heart failure complicated with coronary heart disease, and is beneficial to the improvement of cardiac function, TCM syndrome score and prognosis.